Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Nevro Corp (NYSE: NVRO), a pioneer in neuromodulation therapies for chronic pain management, provides this centralized hub for investors and healthcare professionals to access its latest developments. Track official press releases, clinical milestones, and business updates from the creator of the Senza spinal cord stimulation system.
This resource delivers timely updates on NVRO's FDA clearances, international expansions, and evidence-based innovations like its AI-enhanced HFX platform. Users will find disclosures covering product launches, financial results, and strategic partnerships that shape chronic pain treatment globally.
Key updates include advancements in 10 kHz therapy clinical applications, regulatory approvals across markets, and operational developments impacting patient access. Bookmark this page to stay informed about Nevro's progress in redefining neuromodulation standards through engineering and clinical excellence.
Nevro Corp. (NYSE: NVRO) has announced the appointment of Kevin Thornal as the new Chief Executive Officer and President, effective April 24, 2023. He succeeds D. Keith Grossman, who will take on the role of Executive Chairman. The company reported preliminary, unaudited worldwide revenue of approximately $96.3 million for Q1 2023, reflecting a 10% increase year-over-year, with U.S. revenue of $82.3 million, a 12% growth. Sales related to painful diabetic neuropathy (PDN) are expected to be around $15.6 million, up 160% from the previous year. Nevro maintains its full-year revenue guidance of $445 million to $455 million and anticipates a non-GAAP adjusted EBITDA loss of $5 million to $10 million. Nevro plans to release its full financial results on April 26, 2023.
Nevro Corp. (NYSE: NVRO) announced it will report its financial results for Q1 2023 on April 26, 2023, after market close. A conference call is scheduled for 1:30 pm PT (4:30 pm ET) the same day, allowing investors to engage with management regarding the results. The company specializes in medical devices for chronic pain treatment, having developed the proprietary 10 kHz Therapy that has benefitted over 100,000 patients globally. Investors can access the live webcast or archived recording from the company's website.
Nevro Corp. has launched the HFX iQ spinal cord stimulation (SCS) system in the U.S., following a successful limited market release. This advanced system utilizes artificial intelligence to personalize pain relief based on individual patient data, leveraging over 20 million datapoints from 80,000 implanted patients. The HFX iQ system features an upgradeable implantable pulse generator and a mobile app for real-time adjustments. Nevro aims to lead in SCS therapy innovation, with a decade of experience and over 100,000 patients treated. The company is also seeking approvals in Europe and Australia.
Nevro Corp. (NYSE: NVRO), a leader in medical devices for chronic pain management, announced its participation in the Wells Fargo 2023 Medtech Innovation Spotlight Call Series on March 24, 2023, at 2:00 pm Eastern Time. Key executives, including D. Keith Grossman (Chairman, CEO), Rod MacLeod (CFO), and Dr. David Caraway (CMO), will provide insights into the company's advancements and solutions like the proprietary 10 kHz Therapy™, which has benefited over 100,000 patients. An archived webcast will be available on Nevro's website for those interested in learning more about their innovative approaches to chronic pain treatment.
Nevro Corp. (NYSE: NVRO) reported its Q4 and full-year 2022 financial results, revealing a worldwide revenue of $113.8 million, an 11% increase year-over-year. Notably, sales from the Painful Diabetic Neuropathy (PDN) indication soared 329% to $17.3 million in Q4 2022. The company anticipates Q1 2023 revenue between $94 million and $96 million, reflecting a growth of 9% to 11%. Gross profit for Q4 2022 was $75.2 million with a gross margin of 66.1%. However, it also reported a net loss from operations amounting to $19.4 million.
Nevro Corp. (NYSE: NVRO), a leader in medical devices for chronic pain treatment, announced participation in a fireside chat at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023, at 8:45 am Eastern Time. The chat will feature Keith Grossman, Chairman, CEO, and President, along with Rod MacLeod, CFO, at Citigroup's headquarters in New York, NY. A webcast and archived recording will be available in the investor relations section of Nevro's website. Nevro is known for its 10 kHz Therapy, which has improved the lives of over 100,000 patients.
Nevro Corp. (NYSE: NVRO) will announce its financial results for Q4 and full-year 2022 on February 16, 2023, after market close. The conference call will take place at 1:30 pm PT / 4:30 pm ET to discuss these results. The company aims to improve chronic pain treatment through its innovative 10 kHz Therapy, which has positively impacted over 100,000 patients globally. Investors can access the call via phone or through a live webcast available on Nevro's website. Regular updates regarding investor relations can also be found online.
Nevro Corp. (NYSE: NVRO) announced key data presentations at the 2023 North American Neuromodulation Society Annual Meeting, showcasing its HFX™ 10 kHz Therapy for chronic pain. A total of 18 scientific abstracts, including late-breaking presentations, will be featured. Notable trials include SENZA-PDN, the largest randomized study for painful diabetic neuropathy, and SENZA-NSRBP for non-surgical back pain. Results emphasize the therapy's effectiveness over 24 months. Nevro's commitment to neuromodulation continues, aiming to enhance patient outcomes in underserved populations.
Nevro Corp. (NYSE: NVRO) announced its preliminary, unaudited fourth quarter and full-year 2022 revenue results, indicating a fourth quarter revenue of approximately $113.8 million, growing 11% year-over-year. The company reported a full-year 2022 revenue of about $406.4 million, a 5% increase. For 2023, Nevro forecasts revenue of $445 million to $455 million, representing 10% to 12% growth. CEO D. Keith Grossman plans to retire in 2023 but will stay on as Chairman of the Board. Nevro's Painful Diabetic Neuropathy (PDN) sales surged 332% to $48 million for the year.
Nevro Corp. (NYSE: NVRO) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference, scheduled for January 9, 2023, at 3:45 pm PT / 6:45 pm ET. D. Keith Grossman, the company's Chairman and CEO, will be the presenter. A live webcast and an archived recording will be available on Nevro's website.
Nevro specializes in innovative solutions for chronic pain treatment, notably its proprietary 10 kHz Therapy, enhancing patient outcomes globally.
